SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending as CEO Dr. Patrick Soon-Shiong's high-profile media appearances highlight the company's revolutionary cancer treatments and AI-driven cell therapy, sparking community enthusiasm and frustration over perceived regulatory roadblocks. Investors are closely watching patient testimonials and discussing a potential short squeeze, anticipating significant market movement.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending with high community engagement ahead of the 4/20 cannabis holiday, as supporters highlight its robust culture and claim it's outperforming traditional cannabis stocks. While many advocate for its long-term potential as a "culture coin," others warn of its "pump and dump" characteristics.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is rocketing higher after exceeding Q4 earnings expectations and providing strong Q1 guidance, fueled by robust demand from hyperscale data centers for its 800G and 400G optical transceivers, with the community now debating explosive growth potential and short squeeze mechanics despite recent dilution concerns.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following its recent earnings, which highlighted significant capital expenditure plans and increasing financial leverage despite strong revenue growth, sparking a polarized debate among investors. While many express concern over the company's "debt bomb" and short-term profitability, others see the aggressive spending as a strategic "once-in-a-generation opportunity" to meet insatiable AI infrastructure demand.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as widespread community chatter and speculation about a potential military conflict in the Middle East intensify, driving expectations for a significant surge in crude oil prices and a short squeeze for this low-float energy stock, reminiscent of its past performance during similar global events.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Space and Airborne Systems, Integrated Mission Systems, Communication Systems, and Aerojet Rocketdyne. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne and cyber domains. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land and sea domains. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris Technologies is trending after announcing a $1 billion Department of War investment into its Missile Solutions business, which is slated for a 2026 IPO spin-off, exciting the community and analysts who see it unlocking significant value in a booming defense sector.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending as investors weigh potential massive government contracts, including a recent "skip tracing" deal and inclusion in a $38 billion ICE detention overhaul plan, against recent volatility driven by conflicting reports and community claims of short manipulation amidst strong fundamentals.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen (SG) is trending as its recent earnings report sparks a polarized debate among investors, with many expressing frustration over continued losses and management's strategy. However, others view the sharp price reaction as an opportunity, highlighting new initiatives like wraps and the Infinite Kitchen technology as potential catalysts for a turnaround in the competitive fast-casual market.

Forum Energy Technologies, Inc. designs, manufactures, and distributes products to the oil and natural gas industry. It operates through the Drilling and Completions and Artificial Lift and Downhole segments. The Drilling and Completions segment designs, manufactures and supplies products and solutions to the drilling, subsea, coiled tubing, well stimulation and intervention markets, including applications in oil and natural gas, renewable energy, defense and communications. The Artificial Lift and Downhole segment designs, manufactures and supplies products and solutions for the artificial lift, production and infrastructure markets. The company was founded in 2005 and is headquartered in Houston, TX.

Forum Energy Technologies Inc

Forum Energy Technologies is trending due to a robust earnings report projecting significant 2026 revenue and EBITDA growth, igniting community excitement around the ambitious "FET 2030" plan and its long-term potential. Investors are actively discussing the company's aggressive share buyback program and a potential OIH ETF inclusion, positioning FET as a compelling energy play amidst a perceived bottom in the oilfield services cycle.

NioCorp Developments Ltd. engages in the evaluation, acquisition, exploration, and development of mineral deposits. It focuses on a super alloy materials project in Nebraska for producing niobium, scandium, and titanium. The company was founded on February 27, 1987, and is headquartered in Centennial, CO.

NioCorp Developments Ltd

NioCorp is trending as the community debates its recent $100 million public offering, largely perceived as a pivotal step to secure a substantial EXIM Bank loan, coinciding with its physical mine portal construction and confirmed high-grade critical mineral resources crucial for U.S. strategic supply chains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Aardvark was studying the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome in the trial.</li><li>In September, Acadia Pharmaceuticals scrapped development of intranasal Carbetocin after it failed to meet the key goals in a late-stage PWS trial.</li><li>Soleno Therapeutics’ VYKAT XR is the first approved treatment specifically for hyperphagia in PWS patients.</li></ul><p>Shares of Aardvark Therapeutics (AARD) dived 53% after hours on Friday after the company announced that it is voluntarily pausing its late-stage trial in Prader-Willi Syndrome (PWS).</p><p>The company was studying the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome in the trial. Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.</p><h2 class="st-heading-2">Why Is Aardvark Pausing Trial?</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aardvarktherapeutics.com/news-releases/news-release-details/aardvark-therapeutics-announces-voluntary-pause-phase-3-hero">said</a> that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study. The company is reviewing the data to determine next steps, it said, while adding that it has also paused enrollment and dosing in the trial as it completes its evaluation.</p><p>The firm also added that it no longer expects data from the trail in the third quarter of 2026.</p><h2 class="st-heading-2">Other Names To Quit PWS Drug Development</h2><p>In September, Acadia Pharmaceuticals <a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">scrapped</a> development of intranasal Carbetocin after it failed to meet the key goals in a late-stage PWS trial.</p><p>The company then said that intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials and also announced its intent to stop investigating the drug further.</p><h2 class="st-heading-2">Soleno’s Approved Drug</h2><p>Soleno Therapeutics, meanwhile, received FDA approval of VYKAT XR in early 2025, making it the first approved treatment specifically for hyperphagia in PWS patients.</p><p>However, in August, Scorpion Capital revealed a short position against Soleno stock, alleging several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. Scorpion Capital also stated that it intends to submit an emergency Citizen Petition shortly, requesting that the FDA urge Soleno to conduct a voluntary recall of Vykat XR from the market.</p><p>Weeks later, in September, the company <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-stock-tanks-after-patient-treated-with-drug-dies/chwklo0RdHG">stated</a> in a filing with the Securities and Exchange Commission that it is aware of a serious adverse event reported in the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) involving a deceased patient. However, the existence of a report in the data does not establish causation, the company said.</p><p>Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around AARD rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/AARD">AARD stock</a> has dropped 7% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sls-stokes-retail-anticipation-for-breakout-rally/cZTcDCwRITx">SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts 

The company said that the decision was based on certain cardiac observations made during routine safety monitoring in a healthy volunteer study.

Equity

Aardvark Therapeutics Establishes Ardia Subsidiary To Advance Dermatology Pipeline

(RTTNews) - Aardvark Therapeutics Inc. (AARD) announced on Thursday the formation of Ardia Therapeutics Inc., a wholly owned U.S. subsidiary focused on building a dermatology pipeline...

HC Wainwright Reiterates "Buy" Rating for Aardvark Therapeutics (NASDAQ:AARD)

HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Aardvark Therapeutics in a report on Monday...

Aardvark Therapeutics (NASDAQ:AARD) Trading 12% Higher - Time to Buy?

Aardvark Therapeutics (NASDAQ:AARD) Stock Price Up 12% - Should You Buy...

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twelve brokerages that are covering the stock, Marketbeat...

Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% Higher - Time to Buy?

Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% Higher - Here's What Happened...

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of "Moderate Buy" by Analysts

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat.com...

HC Wainwright Has Negative Outlook for AARD FY2025 Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Research analysts at HC Wainwright reduced their FY2025 earnings estimates for Aardvark Therapeutics in a research note issued to investors...

Aardvark Therapeutics (NASDAQ:AARD) CFO Purchases $43,200.00 in Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) CFO Nelson Sun acquired 3,000 shares of the firm's stock in a transaction that occurred on Thursday, December 11th. The stock was purchased...

Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) CEO Tien-Li Lee purchased 7,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an...

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Aardvark Therapeutics Inc.

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Stocktwits

Stocktwits Polls

Aardvark Therapeutics Inc

Concerns over reversible cardiac safety signals at high doses led to a voluntary pause of the Phase 3 HERO trial for its Prader-Willi Syndrome drug.

Current Price	$12.49
Prev Close	$12.50
Open	$12.26
Dividend Yield	N/A
50-Day Moving Average	$13.60
Beta	1.38
Avg. Volume	183,833.45
PE Ratio	-5.56

52-Week High	$17.94
52-Week Low	$4.88
Market Capitalization	$272.17M
EPS (Annual)	-$0.9489
Price to Book	2.22
Revenue Per Employee	$0.00

AARD
Aardvark Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AARD News

AARDAardvark Therapeutics Inc